StockData
UNITED THERAPEUTICS Corp logo

UNITED THERAPEUTICS Corp (UTHR) stock

UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3022% above fair value
$577.34−6.76 (-1.16%)

Close on Nov 18, 2026Market cap $24.76BP/E 20.7Yield –

United Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

United Therapeutics's operating income for the twelve months ending Jun 30, 2026 was $1.40B, down 3.2% year over year. For fiscal 2025 it was $1.49B, up 8.4% from the year before. Over ten years it grew 7.9% a year on average. The highest annual figure on record is $1.49B in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.49B+8.4%
FY2024Dec 31, 2024$1.38B+16.2%
FY2023Dec 31, 2023$1.18B+20.9%
FY2022Dec 31, 2022$979.70M+76.2%
FY2021Dec 31, 2021$555.90M-6.4%
FY2020Dec 31, 2020$593.60M–
FY2019Dec 31, 2019-$187.60M-123.3%
FY2018Dec 31, 2018$805.40M-1.2%
FY2017Dec 31, 2017$814.90M-23.2%
FY2016Dec 31, 2016$1.06B+51.9%
FY2015Dec 31, 2015$699.00M+29.7%
FY2014Dec 31, 2014$538.80M+84.2%
FY2013Dec 31, 2013$292.50M-30.6%
FY2012Dec 31, 2012$421.65M+32.7%
FY2011Dec 31, 2011$317.78M+85.5%
FY2010Dec 31, 2010$171.31M+565.1%
FY2009Dec 31, 2009$25.76M–
FY2008Dec 31, 2008-$82.06M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$330.80M-9.2%
Q1 FY2026Mar 31, 2026$325.80M-14.9%
Q4 FY2025Dec 31, 2025$356.70M-0.3%
Q3 FY2025Sep 30, 2025$388.50M+13.2%
Q2 FY2025Jun 30, 2025$364.50M+13.9%
Q1 FY2025Mar 31, 2025$382.80M+7.4%
Q4 FY2024Dec 31, 2024$357.70M+37.5%
Q3 FY2024Sep 30, 2024$343.10M+4.9%
Q2 FY2024Jun 30, 2024$319.90M+2.1%
Q1 FY2024Mar 31, 2024$356.30M+25.3%
Q4 FY2023Dec 31, 2023$260.10M+48.1%
Q3 FY2023Sep 30, 2023$327.00M+4.0%
Q2 FY2023Jun 30, 2023$313.40M+55.3%
Q1 FY2023Mar 31, 2023$284.40M-1.2%
Q4 FY2022Dec 31, 2022$175.60M+3.4%
Q3 FY2022Sep 30, 2022$314.30M+37.4%
Q2 FY2022Jun 30, 2022$201.80M-9.2%
Q1 FY2022Mar 31, 2022$288.00M–
Q4 FY2021Dec 31, 2021$169.80M+160.0%
Q3 FY2021Sep 30, 2021$228.70M+3.4%
Q2 FY2021Jun 30, 2021$222.20M+58.1%
Q1 FY2021Mar 31, 2021-$64.80M-138.9%
Q4 FY2020Dec 31, 2020$65.30M+2.8%
Q3 FY2020Sep 30, 2020$221.10M+20.6%
Q2 FY2020Jun 30, 2020$140.50M-36.5%
Q1 FY2020Mar 31, 2020$166.70M–
Q4 FY2019Dec 31, 2019$63.50M-51.7%
Q3 FY2019Sep 30, 2019$183.40M+22.6%
Q2 FY2019Jun 30, 2019$221.40M+1.8%
Q1 FY2019Mar 31, 2019-$655.90M-313.7%
Q4 FY2018Dec 31, 2018$131.50M-5.4%
Q3 FY2018Sep 30, 2018$149.60M-53.8%
Q2 FY2018Jun 30, 2018$217.40M+145.6%
Q1 FY2018Mar 31, 2018$306.90M+16.4%
Q4 FY2017Dec 31, 2017$139.00M-20.2%
Q3 FY2017Sep 30, 2017$323.80M+35.7%
Q2 FY2017Jun 30, 2017$88.50M–
Q1 FY2017Mar 31, 2017$263.60M–
Q4 FY2016Dec 31, 2016$174.20M–
Q3 FY2016Sep 30, 2016$238.60M–

More United Therapeutics figures

See a number that looks wrong?